20 Participants Needed

Stellate Ganglion Block for COVID-19-Induced Olfactory Dysfunction

AM
SK
NF
Overseen ByNyssa F Farrell, MD
Age: 18+
Sex: Any
Trial Phase: Phase 1 & 2
Sponsor: Washington University School of Medicine
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Approved in 1 JurisdictionThis treatment is already approved in other countries

Trial Summary

What is the purpose of this trial?

This trial is testing a treatment called stellate ganglion block, which involves numbing certain nerves in the neck. It aims to help people who have lost their sense of smell and have other long-term symptoms after COVID-19. The treatment works by calming overactive nerve signals to improve these persistent issues.

Do I need to stop my current medications for the trial?

The trial requires that you stop taking blood thinners or antiplatelet agents. Other medications are not specifically mentioned, so it's best to discuss with the trial team.

What data supports the effectiveness of the treatment Stellate Ganglion Block (SGB)?

Research shows that Stellate Ganglion Block (SGB) is effective in managing pain in conditions like Complex Regional Pain Syndrome (CRPS) and facial pain. It has also been explored for non-pain conditions, although the evidence is still being synthesized.12345

Is Stellate Ganglion Block (SGB) generally safe for humans?

Stellate Ganglion Block (SGB) is generally considered a safe procedure, but in rare cases, it can lead to serious complications like retropharyngeal hematomas (a type of throat bleeding) and toxicity from the anesthetics used. These complications require specific management and preventive measures.16789

How is Stellate Ganglion Block (SGB) treatment different from other treatments?

Stellate Ganglion Block (SGB) is unique because it blocks sympathetic nerve signals, which can help control conditions like refractory ventricular arrhythmias that don't respond to other treatments. Unlike many treatments that focus on pain relief, SGB is also being explored for various non-pain conditions, making it a versatile option.1691011

Eligibility Criteria

Inclusion Criteria

Adults age 18 to 70
Ability to read, write, and understand English
You have been diagnosed with COVID at least 12 months prior to study enrollment with self-reported olfactory dysfunction.
See 1 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive sequential stellate ganglion blocks to treat COVID-19-induced olfactory dysfunction and other long COVID symptoms

5-10 days
2 visits (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment

1 month
2 visits (in-person)

Treatment Details

Interventions

  • Stellate Ganglion Block
Participant Groups
1Treatment groups
Experimental Treatment
Group I: Stellate Ganglion BlockExperimental Treatment1 Intervention
The ultrasound guided stellate ganglion blocks will be performed by a pain management specialist with extensive experience performing these blocks. The first SGB at the initial visit will be performed on the right side, and the second SGB will be on the left side 5-10 days after the first SGB, given that the patient tolerated the first SGB.

Stellate Ganglion Block is already approved in United States for the following indications:

🇺🇸
Approved in United States as Stellate Ganglion Block for:
  • Chronic pain management
  • Posttraumatic stress disorder (PTSD) symptoms reduction

Find a Clinic Near You

Who Is Running the Clinical Trial?

Washington University School of Medicine

Lead Sponsor

Trials
2,027
Recruited
2,353,000+

Findings from Research

Stellate ganglion block (SGB) has been found effective for non-pain indications such as reducing cardiovascular sympathetic stimulation and improving blood flow in limbs, with moderate to low certainty based on 24 studies including 19 randomized controlled trials.
SGB is also recommended for alleviating menopausal symptoms like hot flashes, particularly in cases where conventional treatments have failed, although evidence for other non-pain uses remains insufficient.
Stellate ganglion block for non-pain indications: a scoping review.Feigin, G., Velasco Figueroa, S., Englesakis, MF., et al.[2023]
Stellate ganglion block (SGB) significantly reduced facial pain in patients, with a mean visual analog scale (VAS) score dropping from 8.89 to 0.2 after treatment, and this relief was maintained for at least 12 months.
In contrast, patients who received oral medications (tramadol and gabapentin) showed only a moderate reduction in pain, indicating that early administration of SGB is crucial for optimal efficacy in treating facial pain.
Facial pain: a possible therapy with stellate ganglion block.Salvaggio, I., Adducci, E., Dell'Aquila, L., et al.[2022]
Stellate Ganglion Block (SGB) is an effective treatment for upper extremity pain due to Chronic Regional Pain Syndrome (CRPS), and this study compared the effectiveness of ultrasound-guided SGB versus fluoroscopy-guided SGB in 14 patients.
The results indicated that ultrasound guidance for SGB is safer and leads to better improvements in patient disability indexes compared to fluoroscopic guidance, with significant reductions in pain intensity observed over six months.
Effectiveness of Stellate Ganglion Block Under Fuoroscopy or Ultrasound Guidance in Upper Extremity CRPS.Imani, F., Hemati, K., Rahimzadeh, P., et al.[2022]

References

Stellate ganglion block for non-pain indications: a scoping review. [2023]
Facial pain: a possible therapy with stellate ganglion block. [2022]
Effectiveness of Stellate Ganglion Block Under Fuoroscopy or Ultrasound Guidance in Upper Extremity CRPS. [2022]
Effect of Stellate Ganglion Block on Intraoperative Propofol and Fentanyl Consumption in Patients with Complex Regional Pain Syndrome Undergoing Surgical Repair of Brachial Plexus Injury: A Randomized, Double-blind, Placebo-controlled Trial. [2022]
Ultrasound imaging for stellate ganglion block: direct visualization of puncture site and local anesthetic spread. A pilot study. [2022]
Left stellate ganglion block, a rescue treatment for ventricular arrhythmia refractory to radiofrequency catheter ablation: A care-compliant case report. [2022]
[Complication and Anesthetics-induced Toxicity of Stellate Ganglion Block]. [2018]
Postoperative stellate ganglion block to reduce myocardial injury after laparoscopic radical resection for colorectal cancer: protocol for a randomised trial. [2023]
A lateral percutaneous technique for stellate ganglion blockade in rats. [2017]
Effectiveness of cervical sympathetic ganglia block on regeneration of the trigeminal nerve following transection in rats. [2019]
Effects of Stellate Ganglion Block on Analgesia Produced by Cervical Paravertebral Block as Established by Quantitative Sensory Testing: A Randomized Controlled Trial. [2019]